Search Results - Oncology




27 Results Sort By:
Using Nanotechnology to Target Aggressive Cancers
Background: Nanotechnology is emerging as a promising tool to target cancer cells. Gold nanoparticles (GNPs) are preferentially taken up by cancer cells when injected into the blood stream and their safety has been demonstrated in human clinical trials. WSU researchers have designed a unique nanoparticle conjugate that combines a GNP with a small m...
Published: 8/15/2017   |   Inventor(s): Malathy Shekhar, Guangzhao Mao, Yanhua Zhang
Keywords(s):  
Category(s): Life Science, Oncology, Small molecule, Receptors/targets, Nano-based, Drug Delivery, Therapeutics, Diseases
An in vivo QQ-systemic protein delivery technology and applications
BackgroundThis invention contains a new composition of our researchers’ previously patented QQ-protein delivery technology and the in vivo applications of this protein delivery technology via systemic administered proteins for cancer diagnosis and therapy. Many proteins and peptides are used as highly specific and effective therapeutic agent...
Published: 8/3/2017   |   Inventor(s): Jianjun Wang, Qianqian Li, Quan Jiang, Feng Jiang, Michael Chopp
Keywords(s): Cancer Therapies, Drug Delivery
Category(s): Diagnostics, Drug Delivery, Life Science, Oncology, Research tools, Therapeutics
Inhibitors of the ubiquitin E3 ligase BCA2 as anti-cancer therapeutic agents
Background:Breast cancer associated protein 2 (BCA2) is a ubiquitin E3 ligase found in invasive breast cancer. Studies have shown that by decreasing its activity, breast cancer cell growth and invasiveness are diminished. Targeting this ligase and inhibiting its activity could play a role in treatment of breast cancer. A molecular approach to in...
Published: 8/3/2017   |   Inventor(s): Angelika Burger, Andrew Westwell
Keywords(s): Analog or Analogue, Breast Cancer, Cancer, Disease, Drug Target, Enzyme
Category(s): Diseases, Oncology, Therapeutics, Life Science, Research tools
Anti-Cancer Activity of a 2,5-Substituted Pyrimidine
This technology is a novel class of compounds that induce apoptosis in cancerous cells. BackgroundARR molecules (adamantyl-substituted retinoid-related) are a unique class of compounds which have been found to induce apoptosis, or cell death, in a large number of tumor types. SHP plays a role in cellular proliferation. Molecules that Interfere wi...
Published: 8/3/2017   |   Inventor(s): Joseph Fontana, Ramzi Mohammad, Lulu Farhana, Amro Aboukameel, Marcia Dawson, Zebin Xia
Keywords(s): Analog or Analogue, Anti-cancer
Category(s): Life Science, Oncology, Therapeutics, Diseases
Novel Anti-Cancer Therapeutic Strategy to Overcome Cancer Resistance and to Enable Tailoring Treatment
This technology is a gene therapy construct based on modified programmed-cell-death genes involved in intracellular apoptosis. Bypassing the main treatment-resistant mechanisms of cancer offers a new direction, away from broad-spectrum treatments, towards individualized therapies for cancer treatment that carry fewer side-effects. Background &...
Published: 8/3/2017   |   Inventor(s): Karli Rosner
Keywords(s): Anti-cancer, Cancer, Disease, Gene, Melanoma, Target, Therapeutics
Category(s): Life Science, Therapeutics, Diseases, Oncology, Biologicals, Genes
SH80 Combinations
BackgroundSH35/SH80 evolved from an effort to improve upon the anti-tumor activity of XK469. XK469 is a compound, currently in Phase 1 clinical trials. The clinical trials include patients with bladder, breast, colorectal, esophageal, head and neck, kidney, liver, lung, mesothelioma, pancreas and sarcoma cancers. Moving a chlorine atom from one ...
Published: 8/3/2017   |   Inventor(s): Lisa Polin
Keywords(s): Anti-cancer, Compound
Category(s): Life Science, Oncology, Therapeutics
ERK-Mediated Grb7 Phosphorylation: A Biomarker and Potential Therapeutic Target in Her2/Grb7 Amplified Cancers
This invention is a new bio-marker for breast and other cancers that have Her2 and Grb7 gene amplifications, thus providing a therapeutic intervention in Her2/Grb7 amplified cancers.Background40% of breast cancers, as well as several other cancer types, display increased activation of tyrosine kinases from the ErbB family, with Her2 found amplified...
Published: 8/3/2017   |   Inventor(s): Guri Tzivion, Deborah Leicht, Alexander Kaplun, Stephen Ethier
Keywords(s): Biomarker, Biotechnology, Cancer, Cancer Therapies, Therapeutics
Category(s): Diagnostic, Life Science, Oncology
Modified Ectodomain of Human EGFR as a Potential Anticancer Agent
Development of a protein that attenuates EGFR and/or EGFR family members and is comprised of a modified EGFR ectodomain. The protein inhibits signaling via the EGFR and/or EGFR family members. The protein includes a portion of the EGFR (or EGFR family member) and the "U" region epitope of EGFR related protein (ERRP), wherein the portion o...
Published: 8/3/2017   |   Inventor(s): Adhip Majumdar, Arun Rishi, Yingjie Yu
Keywords(s): Breast Cancer, Cancer, Cancer Therapies, Disease, Drug Target, Protein, Therapeutics
Category(s): Life Science, Biologicals, Diseases, Oncology
Para-Amino Substituent on the D Ring of Green Tea Polyphenol Epigallocatechin-3-Gallate as Novel Proteasome Inhibitor and Cancer Apoptosis Inducer
This technology is a group of (-)EGCG analogs with stable and improved anti-tumor activities. Background & Unmet Need:Catechins are a type of plant-derived antioxidant whose biological activities may play an effect on cancer prevention. Green tea has long been lauded to have ingredients that protect cells from the DNA damage that causes cancer...
Published: 8/3/2017   |   Inventor(s): Qingping Dou, Kristin Landis-Piwowar, Tak-Hang Chan, Kumi Osanai
Keywords(s): Anti-cancer, Breast Cancer, Compound, Prostate Cancer
Category(s): Life Science, Oncology, Therapeutics, Diseases
Generation of gp78 null mice
Generation of gp78 null mice WSU Tech#: 15-1291 Technology: Generation of the first preclinical experimental model system for gp78-/- C57BL/6 mice, which spontaneously develops age-related nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), linking endoplasmic reticulum-associated degradation (ERAD) to hepatosteatosis, cirrhosis...
Published: 5/19/2017   |   Inventor(s): Avraham Raz, Andrei Golovko
Keywords(s):  
Category(s): Animal models, Biology, Biomedical, Biotechnology, Drug Delivery, Drug Discovery, Drug Screening, Genomics/Genetics, Life Science, Oncology, Research tools
1 2 3